Study S001217

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02298192
Acronym: DUAL™ VI
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 420
Start: 2014-11-21
Primary completion: 2015-12-23
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec/liraglutide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2012-004625-25; OTHER:U1111-1135-6634

Registered primary outcomes

Change From Baseline in HbA1c [Week 0, week 32]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019871	Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Harris SB, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28124817 DOI	cites ClinicalTrials.gov:NCT02298192; registry reference RESULT:28124817